Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Dermatology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters

Malignant Melanoma Clinical Trials

A listing of Malignant Melanoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (89) clinical trials

Study of MK-3475 in Conjunction With Lymphodepletion TIL and High or Low Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma

Study Groups: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the flip of a coin) to 1 of 2 treatment groups (treatment arms): If you are assigned to Arm A, you will receive high-dose IL-2. If you are ...


A Study of Lymphoseek as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma Rhabdomyosarcoma or Other Solid Tumors Who Are Undergoing Lymph Node Mapping

Open label, non-randomized, multi-center, within-subject comparative study to evaluate the tolerability and the diagnostic utility of Lymphoseek with optional comparison to VBD in pediatric subjects with melanoma, rhabdomyosarcoma, or other solid tumor. Subject age will range from neonatal through 17 years.


Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C) ROS1 or ALK Gene Rearrangements (Fusions)

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.


Study of LOXO-101 (Larotrectinib) in Subjects With NTRK Fusion Positive Solid Tumors (NAVIGATE)

This is a Phase II, multi-center, open-label study of patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3. Patients with NTRK1, NTRK2 or NTRK3 fusion-positive cancers will be identified through molecular assay. LOXO-101 will be administered orally at 100mg twice daily (BID), with each cycle consisting ...


Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors

This study will involve treatment with pembrolizumab, tests and procedures done for safety, and the collection of archival tumor tissue, fresh tumor biopsies, and blood samples for biomarker research (including genetic testing).


Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy

The purpose of this research study is to learn whether patients whose disease grows after being treated with nivolumab or pembrolizumab respond to ipilimumab (Yervoy) alone or in combination with nivolumab (Opdivo).


Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib in Patients With BRAF or NRAS-Mutated Metastatic Melanoma

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to 1 of 2 study groups based on the type of mutation you have. If you are in Group A, you will receive nivolumab, dabrafenib, and trametinib (BRAF-mutated patients). If you ...


A clinical trial sponsored by Massachusetts General Hospital for a research study of Ipilimumab, Nivolumab

This research study is a Phase II clinical trial. Researchers hope to study the effects of the combination of Nivolumab and Ipilimumab. Many cancers use specific pathways (such as PD-1/PD-L1 and CTLA-4) to evade the body's immune system. Nivolumab and ipilimumab work by blocking the PD-1/PD-L1 and CTLA-4 pathways and ...


A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer Non-small Cell Lung Cancer or Melanoma That Has Spread to the Brain

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that has spread to the brain.


A Comparison of Matured Dendritic Cells and Montanide in Study Subjects With High Risk of Melanoma Recurrence

This is a Phase II open label, randomized two-arm study to evaluate the safety, tolerability, and immunogenicity of Poly-ICLC matured DCs as an adjuvant for NY-ESO-1 and Melan-A/MART-1 peptides (ARM A; DC Vaccine) compared to Montanide ISA-51 VG (ARM B; Montanide Vaccine), both with systemic administration of Poly-ICLC on days ...